We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 22:29:19 |
From May 2019 to May 2024
By Marc Bisbal Arias
Novartis AG (NOVN.EB) said Friday that Bruno Strigini, chief executive officer at Novartis Oncology, has decided to retire from the company and the industry due to personal reasons.
Mr. Strigini will step back from the executive committee of Novartis by Dec. 31. and complete the handover in early 2018, the Swiss company said.
Chief Executive Joseph Jimenez thanked Mr. Strigini for his contributions and achievements, citing the successful integration of the GSK oncology-product portfolio that it acquired in 2015, and which he led.
His successor will be announced in due time, it added.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
December 15, 2017 01:33 ET (06:33 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
